KRAS and Nijmegen breakage syndrome: This novel approach may work best as a first-line therapy, as TRAIL receptor activation has recently been reported to promote mutated ki-Ras-driven metastatic progression67 and ki-Ras mutations are detected in relapsed but not primary NBs.68–70